Arrowhead Pharmaceuticals, Inc. announced Javier San Martin, M.D. as the Chief Medical Officer will be leaving the Company, effective as of February 1, 2024. The Company would like to thank Dr. San Martin for his service and for the many contributions he made as Chief Medical Officer and as a member of the executive team. Bruce Given, M.D., who previously served as the Company's Chief Operating Officer and head of Research and Development until his retirement on May 1, 2020, will assist the Company in the orderly transition of Dr. San Martin's departure in Dr. Given?s new role as Chief Medical Scientist.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.57 USD | +1.99% |
|
-1.62% | -16.44% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.44% | 317.58Cr | |
+16.61% | 12TCr | |
+17.75% | 11TCr | |
+17.23% | 2.59TCr | |
-24.11% | 1.93TCr | |
-18.56% | 1.62TCr | |
-18.47% | 1.56TCr | |
-47.75% | 1.46TCr | |
+57.35% | 1.43TCr | |
+5.62% | 1.4TCr |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024